| AC | TH | ACTH | ||
---|---|---|---|---|---|
TA4415V N (%) | Reference trastuzumab N (%) | TA4415V N (%) | Reference trastuzumab N (%) | ||
At least possibly related AE | – | 53 (98.15) | 49 (90.74) | 24 (44.44) | 28 (51.85) |
Serious AE | 1 (0.93) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
Number of subjects reporting at least one grade 3 or 4 AE | 32 (29.63) | 27 (50.00) | 29 (53.70) | 1 (1.85) | 1 (1.85) |
AEs leading to drug discontinuation | 1 (0.93) | 1 (1.85) | 0 (0.00) | 0 (0.00) | 0 (0.00) |